Potential molecular targets associated with the response to NXLLS in Toledo DLBCL cells are identified and an association between the NXLLS response and HDAC-related epigenetic changes is suggested, providing a basis for further investigation of their mechanistic relationships.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults and is characterized by aggressive progression and substantial molecular and clinical heterogeneity. Despite advances in immunochemotherapy, a considerable proportion of patients develop relapsed or refractory disease, highlighting the need to better understand the molecular mechanisms underlying DLBCL. Nei-Xiao-Luo-Li-San (NXLLS), a traditional herbal formulation historically used for nodules and tumor-like masses, provides a pharmacological model for investigating molecular responses and candidate regulatory mechanisms in DLBCL. Methods: NXLLS was chemically characterized to assess its compositional profile and compositional similarity among batches. Its biological effects were evaluated by assessing cell viability, migration, invasion, and cell-cycle progression in Toledo DLBCL cells. Molecular responses to NXLLS were investigated through an integrated approach combining transcriptomic analysis, network pharmacology, and molecular assays. The functional role of ATF5 was further evaluated using lentiviral overexpression and knockdown. Results: Chromatographic profiling provided an exploratory assessment of compositional similarity among NXLLS samples and supported the selection of eight representative compounds using liquid chromatography–mass spectrometry (LC–MS) annotation and high-performance liquid chromatography (HPLC) authentic-standard confirmation. NXLLS reduced cell viability, migration, and invasion in Toledo DLBCL cells within the tested concentration range. At the molecular level, NXLLS was associated with altered cell-cycle distribution and potential G1-phase accumulation at later time points, reduced vascular endothelial growth factor (VEGF)-associated enzyme-linked immunosorbent assay (ELISA) signal, and modulated stress-response genes. RNA sequencing (RNA-seq) revealed transcriptional changes involving stress-response and histone deacetylase (HDAC)-associated epigenetic pathways. Correspondingly, HDAC expression was reduced, whereas acetylated histone H3 lysine 9 (Ac-H3K9) and acetylated histone H3 lysine 27 (Ac-H3K27) levels were increased. ATF5 knockdown recapitulated several cellular and epigenetic changes observed following NXLLS treatment, supporting ATF5 as a potential downstream mediator of the NXLLS response. Conclusions: This study identified potential molecular targets associated with the response to NXLLS in Toledo DLBCL cells, with ATF5 further investigated as a potential downstream mediator. The findings also suggest an association between the NXLLS response and HDAC-related epigenetic changes, providing a basis for further investigation of their mechanistic relationships.
Background The tumor immune microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) displays pronounced heterogeneity, and existing immunotherapeutic approaches achieve only suboptimal outcomes for a considerable proportion of affected individuals. CD161—a C-type lectin receptor whose coding gene is KLRB1—has l...
Er-Wei Li, Ying-Ying Tang, Yuanyuan Wanyan et al.· Frontiers in Molecular Biosc...· 0 citations
This integrative study identifies berberine-related genes with potential causal relevance to DLBCL and prioritizes CYBB as a functionally relevant target linked to apoptosis, immune regulation, and prognosis, highlighting the potential involvement of berberine–CYBB axis underlying berberine activity in DLBCL.
Jie-Wen Tan, Yun-Man Xu, Yue-Ping He et al.· Frontiers in Pharmacology· 0 citations
AIM: Activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) has poor response to standard rituximab combined chemotherapy regimen and poor clinical prognosis. The aim of this study is to investigate the in vitro experimental basis for the clinical application of the three-drug combination (Zanubrutinib, Lenali...
Ting Wei, Xiaoting Liao, Yue Wang et al.· International Journal of Bio...· 0 citations
The results demonstrate that S100A10 is significantly upregulated in HCC and is closely associated with poor prognosis and an immunosuppressive state, and provides a theoretical basis for combinatorial strategies targeting metabolism and immunotherapy.
Jing-Xu Zhang, Gang-Gang Wang, Zhijie Zhou et al.· International Immunopharmaco...· 0 citations
This article systematically elaborates the molecular structure, expression regulatory mechanisms and clinicopathological value of CLDN18.2 based on the data of 58 global clinical trials, and analyzes the current status, existing problems in testing standardization and drug development.
The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...
Sheela R. Damle, Nancy Liu, Xiu-Yun Jiang et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.